Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

Company Overview - Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3] Upcoming Financial Results - Verona Pharma will report its financial results for the first quarter ended March 31, 2025, on April 29, 2025 [1] - An investment community conference call will be hosted at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update [1] - A live webcast will be available on the company's website, and an audio replay will be accessible for 90 days [1]